ABT at a glance
Abbott Laboratories (ABT, SEC CIK 1800) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on July 28, 2026, an 8-K current report on August 20, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Abbott Laboratories (ABT) reported revenue of $44.3 billion (up 5.7% from FY2024) and net income of $6.5 billion. Diluted EPS was $3.72.
- As of June 30, 2026, 73 institutional investment managers tracked by SignalX reported holding Abbott Laboratories (ABT) shares worth $59.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by MCCOY JOHN A. JR. on September 2, 2026 of 27 shares at $109.54 per share.
- In the last 90 days, ABT insiders reported 0 open-market purchases ($0) and 6 open-market sales ($93.1M) on Form 4, a net sale of $93.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $44.3B
- +5.7% vs prior year
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$93.1M
- 13F holders
- 73 funds
- $59.1B · −2 vs prior quarter
- Latest 8-K
- Aug 20, 2026
- Item 7.01 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- IRS tax disputes over 2017-2020 SNODs totaling $1.05B contested, involving income reallocation between U.S. and foreign affiliates
- Malaysian tax authorities assessed $413M capital gains tax on 2023 intercompany share sale; Penang High Court upheld, Abbott appealed in 2025
- Supply chain tariffs and foreign exchange fluctuations increased costs, partially offsetting margin improvement which led to only a 52.6% gross margin in 2025
- Competitive pressure from biosimilars and off-patent medicines expansion in emerging markets challenges Established Pharmaceuticals segment growth
- Debt maturity exposure with $3.0B of $12.9B total debt due in 2026, plus $20B unsecured bridge loan commitment related to Exact Sciences acquisition
Management Discussion & Analysis
- Revenue $44.2B in 2025, up 5.7% YoY excluding foreign exchange impact
- Operating margin 18.2% in 2025 vs 16.3% in 2024; Medical Devices margin 33.7% vs 32.4%
- Best segment: Medical Devices sales up 12.6% (to approx. $19.9B); worst: Diagnostics sales down 4.3% with margin decline to 19.5% from 24.4%
- Cash and short-term investments $8.9B; long-term debt $12.9B; dividends $4.1B, increased 7.1% to $2.40/share in 2025
- 2026 outlook: focus on growth in diagnostics (Alinity platform), medical devices, nutrition product innovation and emerging market pharmaceutical expansion
Business Overview
- Core business model centered on healthcare products and medical technologies, with no new product lines detailed in 2026 filing
- Notable new segment emphasis: merger agreement dated November 19, 2025 with Exact Sciences Corporation
- Strategic shift: Amended and restated By-Laws effective December 12, 2025, indicating governance updates
- Quantitative metric: Allowances for doubtful accounts and product returns increased to $490M in 2025 from $439M in 2024
- Most noteworthy fact: Inclusion of significant merger-related documents and ongoing update of compensation and governance policies in 2026 Proxy Statement
AI summary of the ABT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $12.593B, up 13.0% YoY from $11.142B
- Gross margin 52.5% vs 52.7% YoY, pressured by Exact Sciences amortization and higher costs
- Best segment Diagnostic Products $3.092B, up 42.3%; worst Nutritional Products $2.144B, down 3.1%
- Cash $5.1B vs $8.5B at December 31; operating cash flow $3.8B, up $339M
- Exact Sciences acquisition $20.6B; $20.0B funded through long-term debt and $1.0B share repurchases in six months
AI summary of the ABT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Filing contains signature and cover-page XBRL references only
- No substantive Regulation FD disclosure or investor-actionable operating information provided
Item 8.01: Other Events
- Abbott agreed to resolve Gill and approximately 2,000 additional NEC claims for approximately $670 million
- Settlement avoids approximately $600 million Gill judgment plus accrued interest after Missouri appellate affirmation
Item EX-99.1: Item EX-99.1
- Settlement agreements resolve Gill and claims involving approximately 2,000 individuals for approximately $670 million
- $670 million exceeds approximately $600 million needed to satisfy the Gill judgment and accrued interest
Item 2.02: Results of Operations and Financial Condition
- Filing contains only signature information dated July 16, 2026
- No earnings figures or operating results included in the provided Item 2.02 text
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Board expanded from 12 to 13 directors effective April 24, 2026, increasing governance capacity
- All 12 director nominees elected, though CEO Robert B. Ford received relatively higher opposition at 72.6M shares
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Kevin Conroy appointed to Abbott’s Board on April 24, 2026
- Shareholders approved the 2026 Incentive Stock Program, replacing the 2017 Program
AI summaries of ABT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ABT
Don't miss the next ABT filing
- Alerts as it files. A push when ABT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ABT, by share count.
- Ask anything. An AI agent that reads every ABT filing and answers with sources.
ABT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Ahuja Nita | A | Sep 30, 2026 | 318 | $98.83 |
| Roman Michael F | A | Sep 30, 2026 | 381 | $98.83 |
| Stratton John G | A | Sep 30, 2026 | 397 | $98.83 |
| Conroy Kevin T | A | Sep 30, 2026 | 318 | $98.83 |
| Gonzalez Patricia Paola | A | Sep 30, 2026 | 333 | $98.83 |
| Conroy Kevin T | F | Sep 23, 2026 | 52,507 | $103.99 |
| MCCOY JOHN A. JR. | Sell | Sep 2, 2026 | 27 | $109.54 |
| MCCOY JOHN A. JR. | F | Sep 1, 2026 | 52 | $110.36 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $42.0B | $44.3B |
| Operating Income | - | $6.8B | $8.1B |
| Net Income | $5.7B | $13.4B | $6.5B |
| Op. Margin | - | 16.3% | 18.2% |
| Net Margin | - | 31.9% | 14.7% |
| Balance Sheet | |||
| Total Assets | $73.2B | $81.4B | $86.7B |
| Equity | - | $47.7B | $52.1B |
| ROE | - | 28.1% | 12.5% |
| Per Share | |||
| EPS | $3.26 | $7.64 | $3.72 |
| Cash Flow | |||
| Operating CF | - | $8.6B | $9.6B |
| CapEx | $2.2B | $2.2B | $2.2B |
Source: XBRL data in Abbott Laboratories (ABT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ABT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 73 | $59.11B |
| Q1 2026 | 75 | $66.68B |
| Q4 2025 | 71 | $80.72B |
| Q3 2025 | 73 | $92.32B |
| Q2 2025 | 71 | $89.57B |
| Q1 2025 | 69 | $65.78B |
| Q4 2024 | 65 | $43.50B |
| Q3 2024 | 58 | $22.38B |
- BlackRock+6.88M (+5%)
- Citadel Advisors LLC+6.68M (+349%)
- T. Rowe Price Group+5.51M (+32%)
- AQR Capital Management+2.62M (+167%)
- FMR LLC (Fidelity)+2.58M (+24%)
- JPMorgan Chase & Co−11.67M (-44%)
- D.E. Shaw & Co−3.82M (-72%)
- Morgan Stanley−3.49M (-12%)
- Ameriprise Financial−3.41M (-24%)
- BNY Mellon−2.45M (-20%)
- Blackstone Group−53.9K
- CITIZENS & NORTHERN CORP−3.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 555 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ABT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 8-K | Aug 20, 2026 | - | Analysis | - |
| 4 | Aug 13, 2026 | - | - | - |
| 10-Q | Jul 28, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 10-Q | Apr 29, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 29, 2026 | - | - | |
| 4 | Apr 29, 2026 | - | - | - |
| 4 | Apr 28, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
- ACET · Adicet Bio IncPharmaceutical Preparations
ABT SEC filings: frequently asked questions
Are ABT insiders buying or selling?
In the last 90 days, Abbott Laboratories (ABT) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $93.1 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ABT stock?
As of June 30, 2026, the largest Abbott Laboratories (ABT) holders among the 13F filers tracked by SignalX were BlackRock ($13.8 billion), Vanguard Capital Management LLC ($10.3 billion), State Street Corp ($7.3 billion), Vanguard Portfolio Management LLC ($4.4 billion), Morgan Stanley ($2.4 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ABT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Abbott Laboratories (ABT) reported revenue of $44.3 billion (up 5.7% from FY2024) and net income of $6.5 billion. Diluted EPS was $3.72. The figures come from the XBRL data in the 10-K.
What are the main risks in ABT's latest 10-K?
In the 10-K filed February 20, 2026, Abbott Laboratories (ABT) flagged: IRS tax disputes over 2017-2020 SNODs totaling $1.05B contested, involving income reallocation between U.S. and foreign affiliates. Malaysian tax authorities assessed $413M capital gains tax on 2023 intercompany share sale; Penang High Court upheld, Abbott appealed in 2025. (AI summary of the Risk Factors section.)
What did ABT report in its latest 8-K?
Abbott Laboratories (ABT) filed an 8-K on August 20, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Filing contains signature and cover-page XBRL references only.
What are the latest ABT SEC filings?
Abbott Laboratories (ABT) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on July 28, 2026, an 8-K current report on August 20, 2026 and a Form 4 insider filing on October 2, 2026.
What is ABT's SEC CIK number?
Abbott Laboratories (ABT)'s SEC Central Index Key (CIK) is 1800. EDGAR lists every ABT filing under that number.
Ask anything about ABT
The research agent reads ABT's filings, financials, insider trades and 13F holders, then answers with sources.